{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464392011
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/a
| target = [[CD2]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 288392-69-8
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05847
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Siplizumab''' (MEDI-507) is a novel [[monoclonal antibody]] with a human [[IgG1]], kappa directed to [[CD2]]. The agent has shown potent [[immunomodulatory]] effects, selectively suppressing the function of [[T cell|T]] and [[NK cell]]s, and is currently being tested as a possible treatment for [[psoriasis]] and in the prevention of [[graft-versus-host disease]].<ref>[http://www.clinicaltrials.gov/ct2/results?term=Siplizumab ClinicalTrials.gov]</ref>

== References ==
<references/>

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}